Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage

aprott/iStock via Getty Images Introduction Hims & Hers (NYSE:HIMS) — the viral telehealth platform that aims to help the world feel great through the power of better health — just reported Q2 earnings that obliterated all expectations. Throughout 2024, the stock has rallied as much as 200%, largely driven by the company's tremendous growth and relentless execution. However, much of the rally was driven by the rising popularity and subsequent shortages of GLP-1 drugs — having recently launched its Weight Lo ...